alendronate has been researched along with Osteomalacia in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Osteomalacia: Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment effects on bone quality and remodeling was assessed in postmenopausal women with osteoporosis treated with oral alendronate." | 9.08 | Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. ( Arlot, ME; Chavassieux, PM; Meunier, PJ; Reda, C; Wei, L; Yates, AJ, 1997) |
| "Treatment effects on bone quality and remodeling was assessed in postmenopausal women with osteoporosis treated with oral alendronate." | 5.08 | Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. ( Arlot, ME; Chavassieux, PM; Meunier, PJ; Reda, C; Wei, L; Yates, AJ, 1997) |
| "Osteoporosis and osteomalacia have been observed after gastrectomy and appear to be caused by reduced food intake and absorption, and steatorrhea." | 2.82 | Metabolic bone disorders after gastrectomy: inevitable or preventable? ( Aoyama, T; Atsumi, Y; Rino, Y; Yamada, T; Yukawa, N, 2022) |
| "Alendronate treatment was discontinued and, while a suitable kidney donor was sought, the patient was treated for 6 months with teriparatide, which significantly reduced the osteomalacia." | 1.42 | Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment. ( Collins, JF; Cundy, T; Dray, M; Fratzl-Zelman, N; Gamsjaeger, S; Klaushofer, K; Michigami, T; Paschalis, EP; Roschger, A; Roschger, P; Tachikawa, K, 2015) |
| "Alendronate has been studied extensively by large trials of high quality and its efficacy to reduce the risk of vertebral and nonvertebral fractures is in line with the criteria of evidence-based medicine." | 1.33 | [Drug therapy for prevention of falls and fractures]. ( Ringe, JD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Rino, Y | 1 |
| Aoyama, T | 1 |
| Atsumi, Y | 1 |
| Yamada, T | 1 |
| Yukawa, N | 1 |
| Florez, H | 1 |
| Mandelikova, S | 1 |
| Filella, X | 1 |
| Monegal, A | 1 |
| Guañabens, N | 1 |
| Peris, P | 1 |
| Cundy, T | 1 |
| Michigami, T | 1 |
| Tachikawa, K | 1 |
| Dray, M | 1 |
| Collins, JF | 1 |
| Paschalis, EP | 1 |
| Gamsjaeger, S | 1 |
| Roschger, A | 1 |
| Fratzl-Zelman, N | 1 |
| Roschger, P | 1 |
| Klaushofer, K | 1 |
| Ghose, R | 1 |
| Ringe, JD | 1 |
| Papierska, L | 1 |
| Rabijewski, M | 1 |
| Chavassieux, PM | 1 |
| Arlot, ME | 1 |
| Reda, C | 1 |
| Wei, L | 1 |
| Yates, AJ | 1 |
| Meunier, PJ | 1 |
2 reviews available for alendronate and Osteomalacia
| Article | Year |
|---|---|
Metabolic bone disorders after gastrectomy: inevitable or preventable?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; F | 2022 |
[Glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Female; Fractu | 2007 |
1 trial available for alendronate and Osteomalacia
| Article | Year |
|---|---|
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biopsy; Bone and Bones; Bone Remodeling; Calcification, | 1997 |
4 other studies available for alendronate and Osteomalacia
| Article | Year |
|---|---|
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Fa | 2018 |
Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment.
Topics: Alendronate; Densitometry; Diphosphonates; DNA Mutational Analysis; Fractures, Bone; Genetic Associa | 2015 |
Osteomalacia: recovery of bone density.
Topics: 25-Hydroxyvitamin D 2; Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Back Pain; B | 2004 |
[Drug therapy for prevention of falls and fractures].
Topics: Accidental Falls; Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Evidence | 2006 |